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Evaluating interventions for informed
consent for surgery (ICONS): Protocol for
the development of a core outcome set
Liam J. Convie1,2* , Scott McCain1, Jeffrey Campbell1, Stephen J. Kirk1 and Mike Clarke2
Abstract
Background: The concept of informed consent is fundamental to medical practice. Shortcomings in the process
can lead to patient complaints, litigation, unmet expectations and poor outcomes. Consent research has focused on
developing tools to improve patient recall and understanding. However, the definitions, methods of measurement and
timing of measurement vary widely across the studies that have been done. Although a Cochrane review has reported
that many of these interventions appear to work, the high level of heterogeneity in outcome reporting prevents the
identification of those interventions that work best and why they do so. It is also not clear which outcomes are most
important to each party involved in the consent process and why.
Methods/design: This project will develop a core outcome set for assessing the effects of interventions aimed at
improving informed consent for surgery and other invasive procedures for adult patients with the capacity to consent
for themselves. We will conduct a systematic review of the qualitative and quantitative literature to identify outcomes
used to date in consent research and map these into domains. A series of semi-structured key stakeholder interviews
will also be used to identify relevant outcomes. These processes will produce a list of potential outcomes for assessing
the effects of interventions to improve consent, which will be refined through an international Delphi survey and
consensus webinars involving key stakeholders to produce the core outcome set.
Discussion: The ICONS study aims to develop a core outcome set for use in trials and reviews of interventions designed
to improve the informed consent process for surgery and other invasive procedures. Our aim is that this core outcome
set will reduce the level of selection and reporting bias in consent research and help clinicians to compare tools to
improve consent.
Keywords: Core outcome sets, Consensus methods, Informed consent, Surgery
Background
Consent represents one of the cornerstones of good
medical practice as outlined by the General Medical
Council [1]. Consent is considered to be valid when a
competent patient knows and understands the potential
harms, benefits and alternatives of the intervention and
uses that information to make their decision regarding
treatment and communicates their decision free from
coercion [2]. The consent process continues to be a sig-
nificant challenge for medical practice. It has come to
prominence again in the Montgomery case [3].
In 1999, Mrs Montgomery was an expectant mother
from Lanarkshire in the United Kingdom. Mrs Mont-
gomery also had diabetes mellitus. Women with diabetes
are at higher risk of having larger than normal babies,
which increases the risk of shoulder dystocia. Mrs Mont-
gomery had not been informed of the risk of shoulder
dystocia, as it had been deemed by her obstetrician that
the risk of shoulder dystocia leading to a serious prob-
lem was very small. Mrs Montgomery claimed that if she
had known about the risks of shoulder dystocia, she
would have requested a caesarean section. The shoulder
of Mrs Montgomery’s baby became stuck during child-
birth, resulting in 12 min of cerebral hypoxia, cerebral
palsy and quadriplegia.* Correspondence: lconvie02@qub.ac.uk1Department of General Surgery, Ulster Hospital, Dundonald, UK
2Centre for Public Health, Queen’s University Belfast, Belfast, UK
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Convie et al. Trials          (2018) 19:609 
https://doi.org/10.1186/s13063-018-2986-8
In 2015, the Supreme Court ruling explained the ma-
teriality of risk. That is, if a reasonable patient in Mrs
Montgomery’s position had been informed of the risk of
obstructed labour, and the possibility of caesarean sec-
tion as an alternative method of delivery to avoid that
complication, she would have likely attached significance
to that information.
This ruling represents a significant change in UK med-
ical law. Previously, the level of disclosure expected from
medical professionals had been determined by a reason-
able body of contemporary medical opinion [4, 5]. How-
ever, following the Montgomery ruling, that standard of
disclosure ought to be determined by what is expected
of a ‘reasonable patient’. There may indeed be a third
level of disclosure. Mazur proposes the ‘subjective pa-
tient standard’. That is to say, the clinician should supply
the information that the particular patient in question
would want to know [6]. This clearly would have signifi-
cant implications for clinical practice.
Obtaining informed consent involves a clinician having
a discussion with the patient. Through this conversation,
the clinician will outline the nature of the proposed
intervention, the potential harms and benefits, and the
alternatives. They will also provide an opportunity for
the patient to ask questions about the treatment. This
process may take place in one session or across a num-
ber of meetings and is often augmented with the use of
written, web-based or video information.
Attempts have been made to improve the consent
process by various means, some of which have been tested
in research studies. Stacey and colleagues’ Cochrane review
of decision aids for patients facing health treatment and
screening decisions found high quality evidence to suggest
that decision aids improve patients’ knowledge regarding
their options and reduce their level of decisional conflict
[7]. However, the review was limited by the large amount
of heterogeneity in the outcomes used to determine the ef-
fect of the decision aids in the consent process. Similarly, a
Cochrane review of interventions to promote informed
consent for invasive procedures concluded that interven-
tions to improve consent consistently improved patient
knowledge [8]. However, although knowledge is clearly an
important step in achieving informed consent, the authors
of the review found that the tremendous heterogeneity in
outcomes measured and how they were recorded made
comparisons between studies difficult. They suggested that
future work ought to focus on developing a consensus on
what outcomes should be measured to determine the qual-
ity of informed consent and to use or develop validated
and standardised tools to measure those outcomes. For ex-
ample, in addition to patient recall of consent-related infor-
mation, outcomes such as understanding, decisional
conflict, deliberation, decisional regret, anxiety and satisfac-
tion, among others, might be considered.
Core outcome sets aim to define a set of outcomes
that should be considered essential in the evaluation and
reporting of a particular intervention or condition [9].
There are well-defined guidelines with a growing evi-
dence base to support the use of core outcome sets and
the methodology employed to develop them [9–14]. Spe-
cifically, they should be developed through consensus
methods involving stakeholder groups specific to the
condition or intervention in question. There should be a
strong emphasis on patient involvement in their devel-
opment to ensure that the outcomes defined are person-
ally important as well as clinically relevant [9].
Core outcome sets are likely to reduce the incidence
of reporting bias, which arise because significant findings
are more likely to be reported than those which are not
significant [15]. Selective reporting of outcomes prevents
informed decisions about treatment options and may
have an adverse impact on the allocation of resources
and research planning [16, 17].
The existence of a core outcome set does not pre-
clude the investigation of other outcomes but rather it
provides a minimum set that should be used in all re-
search studies in the specific topic area. Thereby, it
should improve consistency among trial reports and
provide the valuable information needed to support
meaningful systematic reviews and meta-analyses of
similar studies.
Most core outcome sets have been developed to evalu-
ate specific diseases or treatments, but we will develop
one that is somewhat different. This core outcome set
will be designed to evaluate interventions aimed at im-
proving the consent process for people undergoing inva-
sive procedures, rather than evaluating the effects of, for
instance, those invasive procedures.
The scope of this study is restricted to interventions
intended to improve consent in adults (over 18 years
old) who have adequate mental capacity to make their
own decisions regarding consent for surgery and inva-
sive procedures, including endoscopy and dental surgery.
The study has three main aims:
1. To identify a list of outcomes previously reported in
trials of interventions aimed at improving consent
for surgery and invasive procedures or suggested as
relevant in articles discussing consent for treatment
in general.
2. To identify additional outcome measures relevant to
how interventions to improve consent are evaluated
by exploring which outcomes matter to people
involved in the consent process.
3. To define a core outcome set to evaluate
interventions to improve consent for surgery and
other invasive procedures through a Delphi survey
and consensus meetings.
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Methods/design
The development of this core outcome set will be conducted
in accordance with guidelines and recommendations in the
COMET handbook and the COS-STAD recommenda-
tions with reporting conforming with the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
checklist. (See Additional File 1: SPIRIT Checklist)
[9, 18]. The study will follow the steps outlined in Fig. 1.
Systematic review
Criteria for included studies
Included studies will have attempted to investigate the ef-
fects of an intervention to improve or augment the con-
sent process for surgery or other invasive procedures in
adult patients with capacity to consent for themselves.
Studies that have sought to identify the most effective way
of evaluating the quality of consent will also be included.
Eligible studies will be meta-analyses, systematic reviews
and randomised trials. Protocols for as yet unpublished stud-
ies will be included as well as full reports of these research
studies. A sample of non-randomised controlled trials and
prospective cohort studies will be reviewed for additional
outcome measures, but a full systematic review of
non-randomised quantitative research will not be conducted.
Qualitative studies using focus groups, surveys or in-
terviews to determine which aspects are important in
determining the quality of informed consent will be in-
cluded in a separate meta-synthesis.
Exclusion criteria
We will exclude studies that focus on consent for interven-
tions other than surgery or other invasive procedures. For ex-
ample, we will not include studies investigating patients’
decisions to participate in research studies, as issues such as
Fig. 1 Flowchart for the Development of a Core Outcome Set to evaluate the effectiveness of interventions to improve informed consent for surgery
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clinical equipoise and the therapeutic misconception make
consent for participation in research and consent to treat-
ment substantially different. Studies evaluating consent in pa-
tients without capacity or in children (under 18 years) will be
excluded. Consent and assent are generally used to differenti-
ate the legal competency of children over and under 16 years
old, respectively, when they agree to clinical care. Parental
permission is generally accompanied by assent, which indi-
cates a child’s acquiescence, while consent infers a voluntary
positive agreement. The consent process, information needs
and decision-making processes for children differ signifi-
cantly to those for adults consenting for themselves and thus,
studies involving children will be excluded. Studies published
in a language other than English will also be excluded.
Search strategy to identify studies
The systematic review will be undertaken and reported in
accordance with the principles in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement [19].
A search strategy has been designed by a senior med-
ical librarian and further refined through consultation
with the principal investigator (LJC). The search for ex-
perimental studies will seek trials of interventions de-
signed to standardise or improve the consent process for
patients undergoing surgery or other invasive proce-
dures. A separate search strategy will be developed for
finding relevant qualitative studies.
Searches will made of MEDLINE (from 1946 to
August 2017), EMBASE (1974 to August 2017), CINAHL
(from 1937 to August 2017), CENTRAL (as of August
2017), PsycINFO (from 1806 to August 2017) and Web of
Science (as of September 2017) using medical subject
headings. Eligible ongoing and unpublished trials will be
sought in ClinicalTrials.org and the WHO clinical trials
registry platform (ICTRP) using the search term ‘informed
consent’ [20, 21]. References in included studies will be
checked to identify further relevant studies [22].
Eligibility of studies for inclusion
Two reviewers will screen the retrieved titles and ab-
stracts to eliminate irrelevant studies. Full-text articles
will be obtained for all studies considered to be poten-
tially relevant from this initial screening. After reviewing
the full text, any discrepancies in decisions about eligible
studies will be resolved through discussion with a third
senior reviewer.
Data extraction
The two independent reviewers will use a standardised
recording template to extract data from the eligible stud-
ies. This will include study title, study author, study aim,
type of study, study period, publication date, study loca-
tion and number of participants. All primary and
secondary outcomes, how the outcomes were measured
(i.e. using a validated tool or otherwise), the rationale for
the outcome measures chosen, the time point or period,
and how outcomes were reported will all be recorded.
In the review of qualitative studies, each relevant
full-text paper will be analysed independently by two au-
thors. The following key details for each study will be re-
corded: year of publication, country in which the study
was conducted, the phenomenon of interest, context,
qualitative method used, number of participants and cul-
tural setting. Furthermore, all funding sources and any
potential conflicts of interest will be noted. Findings
were defined as the main themes or findings detailed in
the results section of each paper. Findings will be ex-
tracted verbatim from the text of the study with an ac-
companying illustrative quote where available. Each
finding will be graded according to how confident the
reader was in that finding. Unequivocal findings are
those that are a matter of fact, beyond reasonable doubt,
directly reported or observed, or not open to challenge.
Credible findings are plausible interpretations of the pri-
mary data within the selected theoretical framework. How-
ever, since they are interpretations of the primary data, they
are open to challenge. Finally, unsupported findings are
those with no evidence from the primary data.
The methodological quality of the studies included will
be assessed using the Cochrane risk of bias tool for ran-
domised trials [23]. Qualitative studies will be evaluated
using the Joanna Briggs Institute SUMARI software, using
their criteria for appraising the quality of qualitative re-
search [24]. Methodological quality is being assessed to fa-
cilitate the stratification of outcomes reported in studies at
high and low risk of bias.
Data analysis
The data will be summarised in tabular form and coded
according to what is measured. Agreement regarding
outcome coding will be achieved between two re-
searchers with a third senior researcher acting as an
arbiter when necessary. We will repeat the coding of
outcomes into broader outcome domains and con-
stantly compare outcome information with these
emerging domains until all outcomes have been
assigned to an outcome category.
The findings of qualitative studies will be read re-
peatedly before being grouped into categories of simi-
lar findings. Category descriptions were defined through
consensus among the authors. These categories were
reviewed and refined using a constant comparison method.
Following the classification of categories, synthesised find-
ings combining two or more categories were agreed and
developed through consensus among the authors.
The final structure and organisation of the outcome map-
ping process will be achieved through discussion within the
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research team, which includes experts in informed consent,
taxonomy development and patient representation.
If an outcome was measured using a specific tool, details
of that tool will be recorded verbatim to allow comparison
with other tools designed to measure similar outcomes.
This process aims to catalogue comprehensively which
outcomes have been measured in trials of interventions
for informed consent for surgery in the form of an out-
comes taxonomy. We also aim to incorporate the find-
ings from a review of the qualitative literature into the
taxonomy to facilitate the stakeholder consultation com-
ponent of the research.
Identifying items of importance to stakeholders
Stakeholders
Stakeholders with an interest in the consent process and
patients will be invited to participate in semi-structured
interviews to determine which outcomes each stake-
holder group believe to be most important in determin-
ing the quality of consent.
People with expertise in informed consent and patients
will be invited to participate in this phase of the re-
search. It is anticipated that approximately 30 individuals
from a wide range of backgrounds will be included. Pro-
posed stakeholder groups include:
1. Patients
2. Clinicians with an interest in informed consent.




A purposive sample of each stakeholder group will be
identified and sampling will be performed within each
stakeholder group to ensure there is a balance of partici-
pants across the groups. There will be approximately
four to six individual interviews per stakeholder group.
Participants from each group will be identified from the
following sources:
1. Patients involved in qualitative research previously
conducted by our group investigating the question
‘What is important to patients in the consent
process?’ who have indicated that they would be
happy to be involved in future research. These
patients have undergone either emergency or
elective surgery for a wide range of conditions,
including minor day surgery and major surgery for
benign and malignant conditions. Purposive
sampling will ensure there is an adequate
representation of patients from differing
demographic groups and clinical backgrounds.
2. Non-patient groups will be identified through
existing professional networks. If additional
individuals are required, they will be identified
through the following sources:
a. Clinicians with an interest in consent will be
identified through the Association of Surgeons
of Great Britain and Ireland.
b. Solicitors will be identified through the Law
Society of Northern Ireland.
c. Consent researchers and bioethicists will be
identified through the Society for Medical
Decision Making and the Association of
Bioethics, respectively, and through reviewing
the contact details of published researchers.
A sample size of approximately 30 participants is in
line with the interview component of other Delphi
studies and will likely be sufficient to reach satur-
ation. Stopping criteria will be applied within each
stakeholder group. That is, three consecutive inter-
views with no new ideas contributed will indicate data
saturation. These techniques have been demonstrated
to be appropriate for use in qualitative research and
they ensure that the data are representative of the
population being studied whilst not wasting resources
by continuing to conduct interviews when no new
ideas are being presented [25].
Purposive sampling will ensure there is a diverse range
of participants so that a variety of perspectives are cap-
tured on what is important in determining the quality of
informed consent.
Potential participants will be contacted by email to
provide study information and to invite them to partici-
pate in the interview. Interested individuals will be asked
to contact the investigators to arrange a convenient time
to conduct the interview by telephone or Skype.
Informed consent will be obtained using a standar-
dised script before commencing each interview. Tele-
phone and Skype interviews have been chosen over
face-to-face interviews to minimise inconvenience for
participants and to facilitate the inclusion of individuals
over a wide geographic area. These interviews will be
audio-recorded and contemporaneous notes will be kept
by the interviewer.
Conduct of semi-structured interviews
Participants will not be provided with a summary of
the findings from the systematic review prior to the
interview as we do not wish to focus the participants’
attention on previously reported outcomes. Defini-
tions with explanatory notes for each of the outcomes
identified will be developed by the research team and
supplied to participants to improve their
understanding.
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Specifically, participants will be asked to comment on
the relative importance of specific outcomes in determin-
ing the quality of informed consent. They will be asked to
suggest additional outcomes that may be of relevance and
how these may be measured. This will allow identification
of as yet unstudied outcomes. Participants will be asked
which outcomes they believe to be core.
Qualitative data analysis
The analysis of the interviews will begin during the data
collection, to help refine and develop future interviews.
Two reviewers will independently assess the transcripts
to identify key points that stakeholders believe to be im-
portant in the consent process through a constant com-
parison approach [26].
When the dataset is complete, qualitative data will be
analysed within stakeholder groups. The aim of the ana-
lysis will be to define which outcomes are deemed to be
most important and explore the reasons why people be-
lieve they are important.
The data will be analysed using a framework approach,
which is an established qualitative analysis method that
employs constant comparison techniques and grounded
theory [26–28]. The framework method involves the
analyst familiarising themselves with the data, develop-
ing a thematic framework, indexing the data, mapping
the data to the framework and finally interpreting the re-
sults [27, 29]. A second investigator will review the
themes identified.
Ethical approval for the qualitative interviews with
stakeholders has been obtained from the regional ethics
committee (Office for Research Ethics Committees
Northern Ireland reference: RECA 17/NI/0234).
Developing a core outcome set
A Delphi consensus survey will be used to establish
which outcomes are most important to stakeholders in-
volved in the informed consent process. The Delphi con-
sensus model allows participants to respond without
being influenced by others and will facilitate analysis
within stakeholder groups. All participants will have
equal weighting. The process also allows participants to
complete the survey at a time that is convenient for
them and is not bound by geographical or time zone
constraints.
Outcomes included for consensus exercise
The list of outcomes derived from the systematic review
and the semi-structured interviews will be listed individu-
ally within the predetermined outcome domains agreed by
the research group. The survey will be reviewed by the re-
search group for comprehension and pilot tested to ensure
readability and the usability of the online tool.
We will conduct a series of cognitive interviews using
a think aloud technique among a group of patient volun-
teers. The purpose of the cognitive interviews will be to
ensure patients know how to complete the survey, com-
prehend the meaning of the items and understand how to
use the 9-point response scale. Interviews will be conducted
in accordance with best practice in this field [30, 31].
Participants will be asked open-ended questions to:
 Gauge their understanding of the meaning of each
item in the survey
 Understand the clarity of each item from the
patient’s perspective
 Learn how patients interpret the response options
 Identify patient difficulties with the format of the
survey
 Determine the length of time it takes to complete
the survey.
The interviews will be video-recorded and notes on
patient body language recorded as they review the
Delphi survey. After the first five interviews, the survey
will be amended in accordance with patient feedback,
with a further five interviews being subsequently
conducted to determine if any further changes are
necessary.
Identification and recruitment of participants
Stakeholders will be invited to participate in the study
via email. A gatekeeper on behalf of the research team
will contact potential participants. Participants will be
identified and contacted through the following sources:
1. Our existing database of patients who have
expressed interest in participating in future work.
2. Patients who respond to our invitation on the
National Institute for Health Research’s People in
Research website (https://www.peopleinresearch.org/)
3. Non-patient groups will be approached through the
research group’s professional networks in the first
instance. If additional participants are required, they
will be identified as follows:
a. Clinicians with an interest in consent will be
identified through the Association of Surgeons
of Great Britain and Ireland.
b. Solicitors will be identified through the Law
Society of Northern Ireland.
c. Consent researchers and bioethicists will be
identified through the Society for Medical
Decision Making and the Association of
Bioethics, respectively, and by reviewing the
contact details of published researchers. This
group will also contain participants from a legal
background who have published on informed
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consent from jurisdictions other than the
United Kingdom to include an international
legal perspective.
Invitations to participate in the Delphi survey will be
sent by email. Those who are willing to participate can
click on a link in the email that will lead to the online Del-
phi survey. Participants will be asked to register their de-
tails and identify which stakeholder group they belong to.
This will generate a unique ID for each participant. The
system facilitates the linking of participant responses with
their unique ID and will send reminder emails at the end
of week 2 of each 3-week round if necessary.
Consent for completion of the Delphi survey will be
implied by completion of the questionnaire. Participants
will, however, be asked if they would be willing to par-
ticipate in a future web-based consensus agreement
meeting. Ethical approval for the Delphi survey will be
obtained.
The Delphi survey
Participants will be asked to consider the following
question:
Think about the process of consent for surgery. How
important do you think each of the items below would
be in telling you if the process had been performed well?
We will use COMET Delphi manager, a web-based
tool designed specifically for Delphi surveys by the
COMET initiative, to ask participants to score the im-
portance of the listed outcome measures on a 9-point
Likert scale. The scale will be labelled to indicate that a
score of 1 to 3 is of ‘limited importance’, a score of 4 to
6 is ‘important but not critical’ and a score of 7 to 9 is of
‘critical importance’ [32]. A definition of each outcome
will be provided to aid participant comprehension.
Round 1
In addition to being asked to rate the importance of all
the outcomes, participants will be given the opportunity
in round 1 to suggest additional outcomes that had not
been identified previously.
Descriptive statistics will be used to summarise the re-
sults. The frequency distribution, median and interquar-
tile ranges will be calculated from the responses of each
stakeholder group for each outcome. All outcomes that
are included in the initial list for round 1 will be carried
forward to round 2. Any new additional outcomes will
be reviewed and coded by two investigators to ensure
they are independent of the outcomes already listed.
The number of participants starting the survey, the
number completing the survey and the number of
non-respondents will be recorded.
Round 2
Round 2 assumes that adequate numbers responded to
round 1. In this study, we wish to have at least 10 partic-
ipants per stakeholder group before proceeding, which
has been deemed acceptable in previous work [14]. If
the minimum number of responders is not achieved, this
will be discussed by the research group.
The survey for round 2 will present participants with
feedback from all stakeholder groups combined, for each
outcome from round 1. These data will be presented
graphically demonstrating the full spread of scores and
reminding participants of their own response in the pre-
vious round before asking them again to rate the import-
ance of each outcome on the 9-point scale in the
context of the feedback they have received. Participants
will also be given the opportunity to state whether and
why each outcome should be included in the final core
outcome set and to explain why they changed their score
from round 1, if they did so.
There is evidence to support the provision of feedback
from all stakeholder groups in terms of improving consen-
sus, reducing the variability of responses and improving
agreement on those items to keep at the conclusion of the
process [33].
The number of participants completing round 2 will
be recorded and analysed for evidence of response bias
between the round 1 and round 2 feedback groups. De-
scriptive statistics will be used to summarise the re-
sponses to each outcome.
A predetermined standard of 70% of respondents rat-
ing an outcome 7 or higher and less than 15% rating it 3
or lower will rule an outcome in for inclusion in the
core outcome set. Likewise, outcomes with less than
15% of respondents rating it at least 7 and greater than
70% rating it 3 or lower will be excluded from the core
outcome set. Outcomes not meeting these criteria will be
classified as equivocal and will require further work (as de-
tailed below). These standards are in keeping with a grow-
ing body of core outcome set literature [10, 13, 14, 34].
Although the criteria are somewhat subjective, no defined
rules exist for inclusion or exclusion, and bias will be mini-
mised by determining the inclusion and exclusion thresh-
olds at the protocol stage.
Round 3
It is hoped that adequate consensus can be achieved dur-
ing the first two rounds of the Delphi survey so that the
list of outcomes has been distilled down to a manageable
number to take forward to the consensus meetings. If this
is not the case, a third round of the Delphi survey will be
undertaken. Participants will be presented with the distri-
bution of scores for each outcome for each of the stake-
holder groups and reminded of their personal score from
round 2. Participants will then be asked to rescore all
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outcomes and consider whether, and why, they should be
included in a core outcome set. The methodology for this
round will follow the steps outlined in round 2.
Patient participant focus groups
Following completion of the Delphi survey, patients
who have indicated a willingness to be involved in
additional aspects of the research will be invited to
participate in a focus group. They will be shown the
findings of the Delphi survey and their views on
those findings elicited. Specifically, the research team
will ask them to express their views on the import-
ance of those outcomes that were deemed equivocal
from the Delphi process and to confirm whether they
believe that the outcomes that met the criteria for
definite inclusion and exclusion from the core out-
come set were classified appropriately.
Patients will not be included in the subsequent con-
sensus webinars, as previous consensus-building exercises
have found that laypeople are reluctant to contribute fully
in a discussion with perceived experts in such settings.
However, the results from the patient focus group will be
presented to the participants of the consensus webinars.
Web-based consensus meetings
The main objective of the web-based consensus meeting
will be to determine whether to include or exclude out-
comes that were equivocal in the survey portion of the
study.
Participants will have been identified in earlier rounds
of the research as being willing to participate in a con-
sensus meeting. Informed consent will be obtained. The
research team will facilitate the webinars. The meeting
dialogue will be audio-recorded using Adobe Connect Pro
software (Adobe systems Incorporated, San Jose, CA).
The primary focus of the webinars will be to decide
whether equivocal outcomes should be included in the
final core outcome set. However, there will also be an
opportunity for the participants to review the outcomes
already excluded and included, to ensure any minority
opinions can be documented.
A final core set of what outcomes to measure to deter-
mine the effects of interventions to improve informed
consent will be formulated following the two webinars.
Determining how and when to record outcomes is be-
yond the scope of this research. The lack of a tool to
measure any individual outcome will not preclude its in-
clusion in the core outcome set.
Two separate webinars will be conducted involving
different participants. This will:
1. Give me flexibility in the time and date of the
webinars to encourage participation.
2. Allow meetings at different times to facilitate
participation from stakeholders in different time
zones (e.g. North America and Australasia).
3. Allow comparison between the core outcome sets
generated by these independent consensus
webinars.
The research team facilitating the second webinar
will not reference the outcome of the first webinar
during it.
The final core outcome set and its development will
be reported in line with COS-STAR guidance [12].
Statistical considerations
All data will be collected prospectively and entered into
a secure electronic database by members of the re-
search team.
No standardised method of calculating the sample size
for Delphi studies exists. However, there is evidence to sug-
gest that panels of approximately 20 people can produce
stable results [35]. Therefore, to allow for 50% attrition be-
tween rounds, we will aim to recruit a minimum of 40 par-
ticipants per stakeholder group in round 1.
Discussion
Currently, no core outcome set exists for the evaluation of
tools designed to improve the quality of informed consent
for surgery or other invasive procedures. The ICONS
study aims to fill this gap. We hope that this core outcome
set will reduce the level of selection and reporting bias in
consent research and help clinicians to compare tools to
improve consent so that patients are better informed. By
ensuring key stakeholder involvement in all stages of the
development process, we hope that the core outcome set
will be fit for purpose and will be well accepted in future
research internationally.
Trial status
This protocol does not describe a trial. The protocol
outlines the development of a core outcome set to be
used in future trials of interventions to improve in-
formed consent for surgery and other invasive proce-
dures. This study is currently in the set-up phase.
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